{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1","upperLimit":"83","value":"3"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"79","value":"4.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Participants were administered Depsipeptide and cycles (each cycle is 21 days) were monitored from the prescribed dose or higher to determine reductions (if needed) to maintain tolerability.","dispersionType":"Full Range","groups":[{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG000","title":"Peripheral T-cell Lymphoma (PTCL)"},{"description":"Participants received at least one protocol prescribed dose or higher of Romidepsin intravenously at 14mg/m\\^2 and at 17.5 mg/m\\^2 on days 1, 8, and 15 of a 28 day cycle.","id":"OG001","title":"Cutaneous T-cell Lymphoma (CTCL)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"83 cycles (i.e., each cycle is 21 days)","title":"Median Number of Cycles of Depsipeptide Administered","type":"SECONDARY","unitOfMeasure":"Cycles per patient"}